Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction.
Regeneron said it will acquire 23andMe’s genomics service and its bank of 15 million customers’ personal and genetic data as part of the deal. The pharma giant said it plans to use the 23andMe customer data to help drug discovery, and that it will “prioritize the privacy, security, and ethical use of 23andMe’s customer data.”
23andMe filed for bankruptcy protection in March after a data…